» Articles » PMID: 15102693

Prognostic Significance of Activated Akt Expression in Pancreatic Ductal Adenocarcinoma

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2004 Apr 23
PMID 15102693
Citations 105
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Akt is a serine/threonine kinase that plays a central role in tumorigenesis. Among the members of Akt family, Akt2 is associated with the development of human cancers. The present study was designed to clarify the prognostic significance of Akt2 and activated Akt expression in pancreatic ductal adenocarcinoma (PDAC). In addition, activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) and the proliferation activity of tumor cells detected by Ki-67 immunohistochemistry were examined.

Experimental Design: Immunohistochemical analysis was performed on paraffin-embedded specimens from 65 patients with PDAC; 36 males and 29 females with ages ranging from 48 to 79 years (median, 66 years) of age. Expression levels of Akt2, phosphorylated Akt (p-Akt), and phosphorylated ERK 1/2 (p-ERK 1/2) were categorized as either weaker (low intensity) or equal to stronger (high intensity) compared with those in the endothelial cells of the same specimens. For Ki-67 immunohistochemistry, cases were divided into two groups: level 1, Ki-67 labeling index (LI), <20%; level 2, Ki-67 LI, > or = 20%.

Results: Twenty-six (42.6%), 28 (45.9%), 39 (63.9%), and 46 (75.4%) of the tumors showed high intensity of Akt2, p-Akt, and p-ERK 1/2 expression, and Ki-67 LI level 2, respectively. A significant positive correlation was observed between Akt2 and p-Akt expression (P < 0.01). Multivariate analysis revealed that p-Akt expression, Ki-67 LI, and histological differentiation are independent prognosticators for PDAC.

Conclusions: p-Akt expression is a significant prognostic indicator for PDAC. Inhibition of Akt is a possible molecular approach for treatment of PDAC.

Citing Articles

Pancreatic cancer: genetics, disease progression, therapeutic resistance and treatment strategies.

Singh K, Shishodia G, Koul H J Cancer Metastasis Treat. 2023; 7.

PMID: 38107772 PMC: 10722911. DOI: 10.20517/2394-4722.2021.96.


S100PBP is regulated by mutated KRAS and plays a tumour suppressor role in pancreatic cancer.

Srivastava K, Lines K, Jach D, Crnogorac-Jurcevic T Oncogene. 2023; 42(46):3422-3434.

PMID: 37794133 PMC: 10638088. DOI: 10.1038/s41388-023-02851-y.


Recent advances in targeted therapy for pancreatic adenocarcinoma.

Fang Y, Yang W, Niu Y, Sun Y World J Gastrointest Oncol. 2023; 15(4):571-595.

PMID: 37123059 PMC: 10134207. DOI: 10.4251/wjgo.v15.i4.571.


The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.

Ma Y, Sender S, Sekora A, Kong W, Bauer P, Ameziane N Int J Mol Sci. 2022; 23(8).

PMID: 35457111 PMC: 9029322. DOI: 10.3390/ijms23084295.


Nickel's Role in Pancreatic Ductal Adenocarcinoma: Potential Involvement of microRNAs.

Mortoglou M, Manic L, Djordjevic A, Bulat Z, dordevic V, Manis K Toxics. 2022; 10(3).

PMID: 35324773 PMC: 8952337. DOI: 10.3390/toxics10030148.